Advanced Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
Advertisement
Katy MarshallAdvanced Renal Cell Carcinoma | February 21, 2024
Researchers analyzed the data from patients who received anti–LAG-3 and anti–PD-1.
Read More
Saby George, MD, FACPAdvanced Renal Cell Carcinoma | February 15, 2024
Dr. Saby George continues with the survival implications and ramifications from the CheckMate 214 long-term data.
Saby George, MD, FACPAdvanced Renal Cell Carcinoma | February 15, 2024
Dr. Saby George provides details on CheckMate 67T for the utility of subcutaneous nivolumab for advanced or metastatic ccRCC.
Thomas Powles, MBBS, MRCP, MDAdvanced Renal Cell Carcinoma | February 13, 2024
Dr. Powles gives his unique feedback on what to make of KEYNOTE-564 and how aRCC frontline options should be compared.
Rana McKay, MDRenal Cell Carcinoma | February 8, 2024
The panel forecasted some of the major questions that will be answered regarding belzutifan, triplet combinations, and more.
Rana McKay, MDRenal Cell Carcinoma | February 8, 2024
The panel transitioned to relevant considerations from the CheckMate 67T study and thoughts on subcutaneous nivolumab.
Rana McKay, MDRenal Cell Carcinoma | February 8, 2024
The panel highlighted the CheckMate 9ER study and implications for clinical practice.
Rana McKay, MDRenal Cell Carcinoma | February 8, 2024
The panel swapped opinions on data pertaining to CheckMate 914, CheckMate 214, and IMDC selection criteria.
Rana McKay, MDRenal Cell Carcinoma | February 8, 2024
The panel discussed the groundbreaking OS results from the KEYNOTE-564 study and implications for their practice.
Rana McKay, MDRenal Cell Carcinoma | February 8, 2024
The panel considered the role of SBRT as well as MDT in RCC. They also weighed in on variant histology considerations.
Rana McKay, MDRenal Cell Carcinoma | February 8, 2024
The panel weigh the treatment considerations of IO/IO versus IO/TKI for advanced renal cell carcinoma.
Katy MarshallRenal Cell Carcinoma | February 4, 2024
Researchers evaluated the differences between IMDC risk groups, including OS and time to treatment discontinuation.
Naveen Vasudev, MD, PhDAdvanced Renal Cell Carcinoma | January 31, 2024
Dr. Vasudev discusses his recent research comparing the effects of a modified versus standard ipilimumab schedule.
Katy MarshallAdvanced Renal Cell Carcinoma | December 15, 2023
Belzutifan was previously tested in the LITESPARK-005 trial.
Katy MarshallAdvanced Renal Cell Carcinoma | December 12, 2023
The trial compared the effects of administering ipilimumab plus nivolumab following either a standard or modified schedule.
Emily MenendezSUO 2023 | January 31, 2024
Similar to results from the intention-to-treat population, pembrolizumab was favored for its benefit of prolonging DFS.
Zachary BessetteSUO 2023 | January 31, 2024
An analysis compared the outcomes of patients with mRCC who underwent cytoreductive nephrectomy and first-line TKI or IO.
Emily MenendezAdvanced Renal Cell Carcinoma | January 31, 2024
TKI monotherapy and TKI plus non-IO therapy was the most common subsequent treatment utilized after receiving IO-TKI.
Katy MarshallAdvanced Renal Cell Carcinoma | January 31, 2024
Researchers evaluated survival outcomes, demographic data, and clinical presentation.
Emily MenendezAdvanced Renal Cell Carcinoma | January 31, 2024
Past 12 months, the effectiveness and safety between nivolumab plus ipilimumab and pembrolizumab plus axitinib were similar.
Advertisement
Advertisement
Advertisement